Coherus BioSciences Reports First Quarter 2023 Financial Results and Business Highlights

– UDENYCA® autoinjector approved and ready for May 2023 launch –– CIMERLI® product-specific Q-code now facilitating electronic reimbursement following April 1 activation... | May 8, 2023

Related Keywords

United States ,Canada ,China ,Junshi Biosciences ,Denny Lanfear ,Coherus Biosciences ,Marek Ciszewski ,Jodi Sievers ,Klinge Pharma ,Abbvie Inc ,Amgen Inc ,Exchange Commission ,Nasdaq ,Us Centers For Medicare Medicaid Services ,Genentech Inc ,Corporate Communications ,Drug Administration ,Exchange Commission On ,Coherus Biosciences Inc ,Medicaid Services ,Coheru Chairman ,Chief Executive ,Forward Looking Statements ,Private Securities Litigation Reform Act ,Coheru Quarterly Report ,Contact Information ,Consolidated Statements ,Stockholder Deficit ,Nc Stock Exchange ,News ,Information ,Press Release ,Autoinjector ,Approved ,End ,Ready ,Or ,Bay ,023 ,Launch ,Dow ,Ffacilitating ,Lectronic ,Reimbursement ,Following ,Pril ,F Chrs Us19249h1032 ,